Pfizer
NEWS
Robert Hollingsworth, PhD, a former Pfizer executive who oversaw the development of cancer vaccines and immunotherapeutics, has taken on the role of the CSO at Shoreline Biosciences.
Now that Omicron is becoming less common, its sister variant, BA.2, seems to be surging worldwide and in the U.S. For that and more, continue reading.
Many countries around the world that appeared to have kicked COVID-19, are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2, and more COVID news.
BioSpace talked with Paul Mango, one of the key leaders of Operation Warp Speed, about the experience.
Shares of Sanofi took a hit in premarket trading after it announced its Phase II breast cancer study assessing an experimental oral SERD failed to hit the mark.
Pfizer will cease operations within Russia and proceeds from its subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine.
A new study out of Duke University added weight to the determination that asthma in children did not increase infection risk, children slow to get COVID vaccine and more COVID-19 news.
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
The death toll related to COVID-19 is more than 6 million, according to the Johns Hopkins COVID-19 dashboard, but it has long been suspected that the toll is significantly higher.
JOBS
IN THE PRESS